Mutation clustering analyses indicated that the cancer cell fraction of canonical breast cancer gene mutations, including TP53, ARID1B, and FGFR3, decreased with treatment in tumor biopsies from the partial response patient (Supplementary Fig. 5; Supplementary Data 1), consistent with oncogenic tumor clone regression. This evidence concerns the gene ARID1B and cancer.